LANREOTIDE ACETATE
( DrugBank: Lanreotide / KEGG DRUG: Lanreotide acetate )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 67 | Polycystic kidney disease | 1 |
| 73 | TSH-secreting pituitary adenoma | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
| 298 | Hereditary pancreatitis | 1 |
67. Polycystic kidney disease
Clinical trials : 233 / Drugs : 188 - (DrugBank : 54) / Drug target genes : 60 - Drug target pathways : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
73. TSH-secreting pituitary adenoma
Clinical trial : 1 / Drugs : 2 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
85. Idiopathic interstitial pneumonia
Clinical trials : 723 / Drugs : 411 - (DrugBank : 126) / Drug target genes : 104 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
298. Hereditary pancreatitis
Clinical trials : 110 / Drugs : 142 - (DrugBank : 59) / Drug target genes : 61 - Drug target pathways : 154
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|